Quantum-si INC 8-K filings

Quantum-Si Incorporated has appointed PricewaterhouseCoopers as its new independent auditor, replacing Deloitte & Touche, effective for the fiscal year ending December 31, 2024.

Quantum-Si has appointed Charles Kummeth, former CEO of Bio-Techne, as the new independent Chairman of the Board, effective May 27, 2024, while Jonathan Rothberg remains a board member.

Quantum-Si is facing a class action lawsuit alleging breach of fiduciary duty and unfair process related to its merger with HighCape Capital Acquisition Corp.

Quantum-Si Incorporated has amended its charter to remove the cap on the number of directors and set a date for the automatic conversion of Class B common stock to Class A common stock.

Quantum-Si announced its first quarter 2024 financial results, highlighted by the full commercial launch of its Platinum instrument and reaffirmed its full-year financial guidance.

Quantum-Si provides a corporate update, highlighting its full commercial launch, product enhancements, and financial guidance for 2024.

Quantum-Si has appointed Paula Dowdy, a seasoned executive with extensive experience in life sciences and technology, to its Board of Directors, effective March 21, 2024.

Quantum-Si has modified stock option awards for its CEO and CFO, adjusting vesting conditions to be triggered by specific share price targets.

Quantum-Si reports fourth quarter and full year 2023 results, finalizes commercial readiness, and provides 2024 financial guidance.

Quantum-Si has announced the release of its V2 Sequencing Kits for its Platinum protein sequencing instrument, offering increased performance and reduced costs.